Isoquercetin
- Generic Name
- Isoquercetin
- Drug Type
- Small Molecule
- Chemical Formula
- C21H20O12
- CAS Number
- 482-35-9
- Unique Ingredient Identifier
- 6HN2PC637T
- Background
Isoquercetin has been used in trials studying the treatment of Kidney Cancer, Renal cell carcinoma, Advanced Renal Cell Carcinoma, Thromboembolism of Vein in Pancreatic Cancer, and Thromboembolism of Vein VTE in Colorectal Cancer, among others.
AB Science Provides Update on Masitinib and AB8939 Clinical Programs
• AB Science is re-examining the marketing authorization application for masitinib in amyotrophic lateral sclerosis (ALS) with the EMA and Health Canada.
• Phase 1 trial of AB8939 shows promising activity against MECOM-rearranged acute myeloid leukemia (AML), with potential for accelerated FDA approval.
• Masitinib demonstrates potential as an alternative to BTK inhibitors in progressive forms of multiple sclerosis, based on ECTRIMS 2024 data.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath